Clenbuterol 40mcg supplied in a 50 tablet pharmaceutical grade format. Consistent dosing with secure packaging and stable composition.
Format50 Tablets
Concentration40mcg
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Clenbuterol Hydrochloride is a long acting beta 2 adrenergic agonist originally developed as a bronchodilator for the treatment of asthma and respiratory conditions, with a well documented pharmacological profile spanning several decades of clinical and biochemical research. F40 Biotech’s formulation delivers 40mcg per tablet in a 50 count format; a standard unit dose presentation consistent with the concentrations most commonly referenced in clinical and metabolic research literature.
As a selective beta 2 agonist, Clenbuterol binds preferentially to beta 2 adrenergic receptors, producing bronchodilation and a range of downstream sympathomimetic effects well documented in respiratory and metabolic research. Its adrenergic activity stimulates the central nervous system and increases thermogenic activity through beta 2 receptor mediated pathways. A mechanism that has made Clenbuterol a frequently studied compound in research examining metabolic rate, lipolytic activity, and adrenergic receptor pharmacology. Clenbuterol’s relatively long half life of approximately 35–40 hours distinguishes it from shorter acting beta 2 agonists, producing sustained receptor activation from a single daily dose in documented research protocols.
Clenbuterol shares adrenergic receptor activity with Ephedrine but operates through a distinct mechanism where Ephedrine stimulates both alpha and beta receptors through norepinephrine release, Clenbuterol acts as a direct selective beta 2 agonist with no alpha adrenergic activity. This selectivity and receptor specificity makes comparative research between the two compounds a frequently explored area in adrenergic pharmacology literature.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s Clenbuterol meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Ketotifen in beta 2 receptor downregulation studies. Browse CSD’s full oral research compound range for complete sourcing.
Clenbuterol Hydrochloride is a long acting beta-2 adrenergic agonist originally developed as a bronchodilator for asthma and respiratory research. It produces fat loss through direct stimulation of beta-2 receptors on adipocytes, activating hormone sensitive lipase and increasing lipolysis while simultaneously increasing metabolic rate through thermogenic effects on brown adipose tissue. Clenbuterol also demonstrates anti catabolic properties through beta-2 receptor activation in muscle tissue, making it particularly researched in cutting protocols where lean mass preservation alongside fat loss is the objective. Its 35–40 hour half-life means a single daily dose maintains receptor stimulation throughout the day and into the following day.
40mcg is the most widely used starting dose for Clenbuterol research in male subjects, matching the standard pharmaceutical tablet dose and the most common entry level dose in the clinical and performance research literature. Female research protocols typically start at 20mcg daily; achievable by splitting a 40mcg tablet. Common male research protocols begin at 40mcg daily and titrate upward by 20–40mcg every 2–3 days until the target dose of 80–120mcg daily is reached, based on individual beta-2 receptor sensitivity and cardiovascular tolerance. The 40mcg tablet allows straightforward dose escalation in precise increments.
The two weeks on, two weeks off cycling protocol is the most commonly researched Clenbuterol administration schedule, based on the observation that beta-2 receptor downregulation occurs with continuous Clenbuterol exposure, reducing thermogenic and lipolytic efficacy over time. By cycling two weeks on followed by two weeks off, beta-2 receptor density partially recovers during the off period, restoring sensitivity to Clenbuterol's effects when the next on cycle begins. Some research protocols use Ketotifen; an antihistamine with beta-2 receptor upregulating properties during Clenbuterol on cycles to attenuate receptor downregulation and extend effective continuous use duration.
Clenbuterol's most commonly researched side effects are dose dependent and related to its adrenergic stimulant properties; hand tremors, elevated heart rate, increased blood pressure, insomnia, and muscle cramps. Tremors and elevated heart rate are the most consistently reported effects, particularly at the beginning of a protocol before adaptation occurs. Taurine supplementation (3–5g daily) is the most commonly researched intervention for Clenbuterol induced muscle cramps; as Clenbuterol depletes taurine stores in muscle tissue. Adequate potassium and electrolyte intake supports cardiovascular function during Clenbuterol research. Dose titration starting at 40mcg and escalating gradually minimizes the severity of initial side effects.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming concentration accuracy at 40mcg per tablet and compound identity as Clenbuterol Hydrochloride. A certificate of analysis is available.
